Theravance Biopharma, Inc. $TBPH Position Cut by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft trimmed its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 58.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,100 shares of the biopharmaceutical company’s stock after selling 31,400 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Theravance Biopharma were worth $413,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. James Investment Research Inc. bought a new position in Theravance Biopharma in the 4th quarter worth approximately $278,000. UBS Group AG lifted its position in Theravance Biopharma by 10.9% in the fourth quarter. UBS Group AG now owns 570,425 shares of the biopharmaceutical company’s stock worth $10,673,000 after purchasing an additional 56,255 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 515 shares during the period. Brookwood Investment Group LLC lifted its position in Theravance Biopharma by 53.6% in the fourth quarter. Brookwood Investment Group LLC now owns 32,367 shares of the biopharmaceutical company’s stock worth $606,000 after purchasing an additional 11,290 shares during the period. Finally, Ellsworth Advisors LLC acquired a new stake in Theravance Biopharma in the fourth quarter worth approximately $670,000. 99.10% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

TBPH has been the subject of a number of research analyst reports. Zacks Research upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Thursday, March 19th. Oppenheimer downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. Wall Street Zen downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday. BTIG Research restated a “buy” rating and issued a $21.00 target price on shares of Theravance Biopharma in a research report on Friday, March 20th. Finally, Weiss Ratings downgraded Theravance Biopharma from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $21.83.

Insider Activity

In other news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the sale, the senior vice president owned 232,699 shares in the company, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.65% of the stock is owned by insiders.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH opened at $16.22 on Friday. Theravance Biopharma, Inc. has a one year low of $9.04 and a one year high of $21.03. The stock has a fifty day moving average of $15.74 and a 200-day moving average of $17.45. The company has a market capitalization of $836.14 million, a PE ratio of 7.37 and a beta of 0.19.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of $17.70 million during the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. As a group, research analysts forecast that Theravance Biopharma, Inc. will post 0.95 EPS for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.